---
schema_version: "secwatch.filing_event.v1"
accession: "0001072613-23-000453"
form_type: "8-K"
ticker: "NTIP"
cik: "0001065078"
company_name: "NETWORK-1 TECHNOLOGIES, INC."
filed_at: "2023-09-06T23:59:59+00:00"
generated_at: "2026-06-10T23:13:11.889324+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Network-1's investee ILiAD reports positive Phase 2b results for pertussis vaccine BPZE1

## Summary
- ILiAD's BPZE1 intranasal vaccine met primary endpoint protecting against B. pertussis colonization (p=0.03) in CHAMPION-1 study.
- Vaccine reduced B. pertussis bacterial burden by 98.0% compared with placebo; no serious adverse events.
- Network-1 holds ~6.8% stake in ILiAD from $7M investment.
- ILiAD plans to present full data at World Vaccine Congress on Oct 19, 2023.

## SEC filing metadata
- accession: 0001072613-23-000453
- form_type: 8-K
- ticker: NTIP
- cik: 0001065078
- company_name: NETWORK-1 TECHNOLOGIES, INC.
- filed_at: 2023-09-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1065078/000107261323000453/0001072613-23-000453-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1065078/000107261323000453/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001072613-23-000453
- JSON: https://secwatch.observer/filing/0001072613-23-000453.json
- Plain text: https://secwatch.observer/filing/0001072613-23-000453.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.